Chugai Group
|
Contact Us
|
Sitemap
About
Company Profile
Our Mission, Vision and Values
Meet Our CEO
Meet Our Chairman
Meet Our Directors
Our History
Chugai Japan
Science
Antibody Engineering Technology
Cyclic Peptide Technology
People
Research Division
Admin Division
LabStories
Careers
Job Openings
FAQs
Sustainability
Initiative For Society
News
News Release
Company Events
Media
Company Brochure
Publications
Meeting Conferences
Collaboration
Search for:
Search for:
Contact
About
Company Profile
Our Mission, Vision and Values
Meet Our CEO
Meet Our Chairman
Meet Our Directors
Our History
Chugai Japan
Science
Antibody Engineering Technology
Cyclic Peptide Technology
People
Research Division
Admin Division
LabStories
Careers
Job Openings
FAQs
Sustainability
Initiative For Society
News
News Release
Company Events
Media
Company Brochure
Publications
Meeting Conferences
Collaboration
About
Find out more
About
Find out more
Sustainability
Find out more
Sustainability
Find out more
News Releases
Chugai Obtains Regulatory Approval for First Tablet for SMA, Evrysdi
Source: Chugai Pharmaceutical: News Releases
March 27, 2025
Anti-CD20 Monoclonal Antibody Rituxan® Approved for Treatment of Frequently Relapsing or Steroid-Dependent Nephrotic Syndrome in Childhood That Has not yet Become Intractable
Source: Chugai Pharmaceutical: News Releases
March 27, 2025
Chugai Selected as a “Nadeshiko Brand”
Source: Chugai Pharmaceutical: News Releases
March 24, 2025
More news
Science and Technology
Find out more
Science and Technology
Find out more
Careers at Chugai
Join us
Careers at Chugai
Join us
Videos
CPR celebrates 10th Anniversary
More videos
Automated page speed optimizations for fast site performance